Skip to main content

Forma, Novartis in Protein Interaction Screening Deal

NEW YORK (GenomeWeb News) – Forma Therapeutics today said that it will collaborate with Novartis on screening drug candidates for oncology applications.

The Cambridge, Mass.-based firm said that it would utilize its cell-based screening platform to identify inhibitors for undisclosed protein-protein interaction targets. Financial and other terms of the alliance were not disclosed.

Steven Tregay, CEO of Forma, said that the alliance with Novartis "provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery."

Filed under

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.